Delcath Systems, Inc. DCTH 深 滬
等待開盤 04-02 09:30:00 美东时间
9.54
+0.260
+2.80%
華盛通- 最 高9.625
- 今 開9.40
- 成交量 30.62万股
- 最 低 9.35
- 昨 收 9.28
- 總市值 3.31亿
- 52周最高 18.23
- 市盈率 靜 141.12
- 換手率 0.88%
- 52周最低 8.12
- 委 比 16.59%
- 總股本 3474.62万
- 歷史最高 9368800000.00
- 量 比 1.11
- 振 幅 2.96%
- 歷史最低 2.25
- 每 手 1
- 風險率 2.09%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 最高300美元！大摩、小摩、花旗纷纷上调英伟达目标价；赛富时、C3.ai、Snowflake、Trade Desk等遭数十家机构下调目标价
今日重点评级关注：HC Wainwright & Co.：维持NovoCure"买入"评级，目标价从47美元升至49美元；Citizens：维持Ironwood医药"跑赢大市"评级，目标价从8美元升至10美元
02-27 11:07
Delcath Systems shares are trading lower. The company reported Q4 financial results.
Delcath Systems shares are trading lower. The company reported Q4 financial res...
02-26 23:50
Delcath Systems FY2026 Total CHEMOSAT and HEPZATO KIT Revenue expected to be more than $100.000M vs $112.895M Est
Delcath Systems (NASDAQ:DCTH) FY2026 Total CHEMOSAT and HEPZATO KIT Revenue expected to be more than $100.000M vs $112.895M Est
02-26 22:18
Earnings Scheduled For February 26, 2026
Companies Reporting Before The Bell • Enovis (NYSE:ENOV) is estimated to report...
02-26 19:11
美股大行评级 | 瑞穗上调英伟达、谷歌、美光科技、SanDisk多家科技股目标价；中金首予诺和诺德"跑赢大市"评级，目标价73.5美元
今日重点评级关注：Needham：维持Cartesian Therapeutics"买入"评级，目标价从40美元升至42美元；Piper Sandler：维持Acrivon Therapeutics"超配"评级，目标价从6美元升至8美元
01-12 14:09
HC Wainwright & Co. Reiterates Buy on Delcath Systems, Maintains $30 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Delcath Systems (NASDAQ:DCTH) with a Buy and maintains $30 price target.
01-10 01:30
Delcath Systems Publishes Phase 3 FOCUS Subgroup Analyses Showing Consistent Efficacy And Safety Of HEPZATO KIT In Unresectable Metastatic Uveal Melanoma In The Journal Of Cancer Research And Clinical Oncology
Delcath Systems, Inc. (NASDAQ:DCTH), ("Delcath" or the "Company") an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of results from
2025-12-31 21:03
Delcath Systems 10-Year Data From Retrospective Study On Patients With Liver-Dominant Metastatic Uveal Melanoma Shows Safety, Efficacy Of CHEMOSAT
Delcath Systems, Inc. (Nasdaq: DCTH), ("Delcath" or the "Company") an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of a retrospective
2025-12-04 05:06
Delcath Systems Announces $25M Buyback Plan
Delcath Systems, Inc. (NASDAQ:DCTH), ("Delcath") an interventional oncology company focused on the treatment of primary and metastatic cancers to the liver, today announced that its Board of Directors has authorized a
2025-11-21 05:02
Delcath Systems Announces Retrospective Study From The University Of Tubingen, Analyzing Long-Term Survivors With Liver Metastases From Uveal Melanoma
Delcath Systems, Inc. (NASDAQ:DCTH), ("Delcath" or the "Company") an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of results from a
2025-11-13 21:39
